Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Ya-Min Yang¹, Yi-Wei Wang¹, An Ta², Elizabeth Vinand², Megan Rutherford², Liping Huang³

¹Pfizer Inc., Taipei, Taiwan.

²Cytel, Inc., London, UK.

³Global Value and Evidence, Vaccines, Pfizer Inc., Collegeville, PA, USA.

PubMed PMC DOI PDF

Abstract

Following 13-valent pneumococcal conjugate vaccine (PCV13) introduction in Taiwan, pneumococcal disease incidence declined; however, incidences driven by non-PCV13 serotypes highlight the need for broader serotype coverage. In response to recent approval of 20-valent PCV (PCV20) for Taiwanese children, this study evaluated 1) health and economic impact of PCV20 in Taiwan's pediatric National Immun…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.